2022 Revenues ($USD) : $429,909,000
2022 R&D spend : $57,752,000
2022 Number of Employees : 900
Fiscal Year End : 6/30/2022
Company CEO : Suzanne Winter, CEO and president

Accuray develops the CyberKnife system, designed to treat diseases in the head and base of the skull as well as functional disorders. The CyberKnife system employs radiosurgery but without the use of a fixed frame bolted to the patient’s head. Ten-year data from a study of men and women with trigeminal neuralgia (TN) demonstrated pain relief after the image-guided robotic radiosurgery treatments. Accuray also appointed a new chief commercial officer and chief accounting officer in 2022. –SW